Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins--reduction of circulating proinflammatory and procoagulatory markers.

Heparin-mediated extracorporeal LDL precipitation treating a peripheral arterial disease patient suffering from repeated postoperative bypass occlusion.

Acute occlusion of a peripheral artery is a serious complication in peripheral arterial disease (PAD). Traditionally open surgical intervention in combination with antithrombotic therapy is the choice for treatment but the beneficial effects of both strategies are limited often by the patient's situation and therapeutic side effects. Heparin-mediated extracorporeal low-density lipoprotein preci...

[Heparin-induced extracorporeal LDL precipitation (H.E.L.P.)].

The H.E.L.P procedure (heparin-induced extracorporeal LDL precipitation) is a selective and sophisticated apheresis procedure. By means of heparin and lowering the pH level, lipoproteins and fibrinogen are reduced by 50-60%. In addition to lipoprotein (a) reduction (50- 60%) adhesion molecules (ICAM- 1, VCAM-1, P selectin), which play a major role in the development and progression of atheroscl...

Pathophysiology of Preeclampsia and Rationale for Heparin-mediated Extracorporeal Low-density Lipoprotein Precipitation as a Possible Therapeutic Approach

Lipid apheresis: oxidative stress, rheology, and vasodilatation

In the treatment of homozygous and therapy-resistant hypercholesterolemia, lipid apheresis enables not only low density lipoprotein (LDL) cholesterol to be lowered by approximately 60%, but also oxidative stress factors to be influenced and adhesion molecules reduced. This was investigated in a group of 12 patients using the heparin-induced extracorporeal LDL precipitation (H.E.L.P.) procedure....

Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report

INTRODUCTION Lipoprotein glomerulopathy is a glomerulonephritis which was described for the first time by Saito in 1989 and is currently acknowledged as a separate nosological entity. It is histologically characterized by a marked dilatation of the glomerular capillaries and the presence of lipoprotein thrombi in the glomerular lumens. The dyslipidemic profile is similar to that of type III dys...